Eledon Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Eledon Pharmaceuticals şirketinin toplam hissedar öz sermayesi $76.1M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $114.6M ve $38.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$78.19m
Eşitlik	US$76.06m
Toplam yükümlülükler	US$38.52m
Toplam varlıklar	US$114.58m

Son finansal sağlık güncellemeleri

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Mar 22

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Dec 05

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Aug 10

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Apr 27

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Jan 05

Recent updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Mar 22

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Dec 05

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Aug 10

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Apr 27

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Jan 05

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Jul 18

Eledon gives update on development strategy for AT-1501 in renal transplantation

Apr 26

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Apr 14

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Feb 21

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Dec 30

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Dec 18

Novus Therapeutics EPS misses by $3.76

Nov 16

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

Nov 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ELDN 'nin kısa vadeli varlıkları ( $81.5M ) kısa vadeli yükümlülüklerini ( $12.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: ELDN şirketinin kısa vadeli varlıkları ( $81.5M ) uzun vadeli yükümlülüklerini ( $26.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ELDN borçsuzdur.

Borcun Azaltılması: ELDN un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ELDN şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: ELDN serbest nakit akışı tahminlerine göre 11 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/06 09:19
Gün Sonu Hisse Fiyatı	2025/01/03 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Eledon Pharmaceuticals, Inc. 8 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Edward Woo	Ascendiant Capital Markets LLC
Alethia Young	Cantor Fitzgerald & Co.
Pete Stavropoulos	Cantor Fitzgerald & Co.

Eledon Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Eledon Pharmaceuticals, Inc. announced delayed 10-Q filing

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Recent updates

Price target decreased by 20% to US$12.50

Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million.

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Eledon Pharmaceuticals, Inc. announced delayed 10-Q filing

Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc., Annual General Meeting, Jul 10, 2024

New major risk - Shareholder dilution

Price target decreased by 10% to US$14.00

Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding

New minor risk - Share price stability

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical Officer

Insufficient new directors

Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of Directors

Price target decreased by 10% to US$16.50

Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023

Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

New major risk - Financial position

Eledon Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Price target decreased to US$19.40

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Eledon Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Eledon Pharmaceuticals, Inc. Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Eledon Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1B Trial Evaluating Tegoprubart in Kidney Transplantation

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

Eledon Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

Eledon Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$28.80

Price target decreased to US$29.75

Senior VP of Administration & Principal Accounting Officer Jon Kuwahara has left the company

Chief Financial Officer recently bought US$89k worth of stock

Eledon Pharmaceuticals, Inc. Announces Update on Development Strategy for AT-1501 in Renal Transplantation

Eledon gives update on development strategy for AT-1501 in renal transplantation

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Eledon Pharmaceuticals, Inc. Announces Appointments of Paul Little as Chief Financial Officer

New 90-day low: US$12.66

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from NASDAQ Composite Index

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

New 90-day low: US$14.76

Price target raised to US$35.00

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Novus Therapeutics, Inc. Appoints June Lee to the Board of Directors

Novus Therapeutics EPS misses by $3.76

Novus Therapeutics, Inc. to Report Q3, 2020 Results on Nov 16, 2020

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

New 90-day high: US$21.42

Novus Therapeutics, Inc. announced that it has received $108.15 million in funding from a group of investors

Novus Therapeutics, Inc. announced that it expects to receive $108.15 million in funding from a group of investors

Novus Therapeutics, Inc. Announces Resignation of Gregory Flesher as Chief Executive Officer

New 90-day low - US$0.41

New 90-day low - US$0.44

Novus Therapeutics, Inc.(NasdaqCM:NVUS) dropped from Russell Microcap Value Index

Finansal Durum Analizi